文献速递眼底病与葡萄膜炎

病理性近视眼球形状与长期预后

Pathologic Myopia Globe Shape and Long-Term Prognosis.
PubMed 文献 · JAMA Ophthalmol · 2026-01-01

该前瞻性队列研究纳入高度近视眼,用高分辨率MRI将眼球形状分为6类,随访15年。结果发现鼻侧变形和圆锥形眼轴增长更快、脉络膜变薄和近视性黄斑变性进展风险更高,提示基线眼球形状可用于风险分层。

要点

  • 基于MRI的3D眼球形状可分为6类,其中4类为变形类型。
  • 鼻侧变形眼轴年增长比非变形快0.050 mm/y,快速伸长风险高5.74倍。
  • 变形眼黄斑脉络膜变薄风险高7.24倍,鼻侧变形和圆锥形风险最高。

核心结论

  • 3D眼球形状是高度近视长期结构功能结局的重要决定因素。
  • 鼻侧变形和圆锥形表型风险最高,支持基线眼球形状分层用于个体化管理。

研究设计与样本

  • 前瞻性队列研究,纳入中山高度近视队列中双眼等效球镜≤-6.00 D的参与者。
  • 基线评估始于2011年8月,每两年随访至2025年9月,共分析152眼(来自95名参与者),平均年龄32.3(14.1)岁,女性占50.7%。

主要发现

  • 眼轴伸长呈形态依赖梯度,球形眼最慢(0.045 mm/y),鼻侧变形眼最快(0.095 mm/y)。
  • 鼻侧变形和圆锥形眼脉络膜变薄及近视性黄斑变性进展风险最高,且视野缺损风险升高。

关键数值与推荐

  • 高度近视定义为双眼等效球镜≤-6.00 D。
  • 快速伸长为眼轴年增长≥0.10 mm/y。
  • 黄斑脉络膜变薄定义为中心凹下脉络膜厚度<62 µm。
  • 视觉损害定义为最佳矫正视力≤20/40。
  • 眼球形状分为球形、椭球形、圆锥形、鼻侧变形、颞侧变形和桶形,前两者为非变形,其余为变形。

临床怎么用

  • 对高度近视患者可考虑基线MRI眼球形状评估以进行风险分层。
  • 鼻侧变形或圆锥形眼球形状者应加强眼轴、脉络膜厚度和黄斑变性的监测。
  • 眼球形状信息可辅助个体化随访计划和早期干预决策。

局限性

  • 样本量较小,仅152眼完成随访,来自单中心。
  • 部分形状亚型(如颞侧变形和桶形)眼数很少,结果需谨慎解读。
  • 研究未报告基于眼球形状干预的效果,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Three-dimensional (3D) eye shape may play a critical role in predicting long-term structural and functional outcomes in high myopia. OBJECTIVE: To determine whether 3D eye shape subtypes defined by high-resolution magnetic resonance imaging (MRI) predict 15-year structural and functional outcomes in high myopia. DESIGN, SETTINGS, AND PARTICIPANTS: This prospective cohort study involved a subsample of individuals with high myopia (spherical equivalent ≤-6.00 D in both eyes) enrolled in the Zhongshan High Myopia Cohort at a single center in China. Participants underwent biennial ophthalmic examinations over 15 years. Baseline assessments began in August 2011, with biennial follow-ups through September 2025. Data were analyzed from October 2025 through December 2025. EXPOSURES: Eye shape was classified into the following 6 categories: spheroidal, ellipsoidal, conical, nasally distorted, temporally distorted, and barrel shaped. Spheroidal and ellipsoidal types were defined as nondeformed and the others as deformed. MAIN OUTCOMES AND MEASURES: The primary outcomes were annual axial elongation rate, rapid elongation (≥0.10 mm/y), macular choroidal thinning (subfoveal choroidal thickness <62 µm), progression of myopic macular degeneration (MMD), incidence of posterior staphyloma, visual impairment (best-corrected visual acuity ≤20/40), and visual field defects. RESULTS: Of 190 eyes from 95 participants, 152 eyes completed follow-up and were included in the analysis. Of the 152 eyes analyzed, 77 (50.7%) were from female participants, with an overall mean (SD) age of 32.3 (14.1) years. Baseline shapes included spheroidal (83 eyes [54.6%]), nasally distorted (25 [16.4%]), conical (23 [15.1%]), ellipsoidal (11 [7.2%]), temporally distorted (5 [3.3%]), and barrel shaped (5 [3.3%]). Axial elongation followed a morphology-dependent gradient, from slowest in spheroidal eyes (0.045 mm/y) to fastest in nasally distorted eyes (0.095 mm/y). After multivariable adjustment, nasally distorted eyes elongated by 0.050 mm/y (95% CI, 0.020-0.080 mm/y; P = .001) faster and had higher odds of rapid elongation (odds ratio, 5.74; 95% CI, 1.66-19.82; P = .006). Deformed eyes overall had a 7-fold higher risk of macular choroidal thinning (odds ratio, 7.24; 95% CI, 1.77-29.63; P = .006). Nasally distorted and conical eyes showed the greatest risks for both choroidal thinning and MMD progression. For visual field defects, risk was elevated in nasally distorted and conical eyes. CONCLUSIONS AND RELEVANCE: Findings from this prospective cohort study suggest that 3D eye shape is an important determinant of long-term outcomes in high myopia. Nasally distorted and conical phenotypes conferred the greatest risks, highlighting the potential value of baseline eye shape stratification for personalized management, risk prediction, or early intervention. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN56368396.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Xiong R, Tan S, Li Y, et al. Pathologic Myopia Globe Shape and Long-Term Prognosis. JAMA Ophthalmol. 2026. PMID: 42207540. doi:10.1001/jamaophthalmol.2026.1561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。